The Concern about Seronegative RA A current review of seronegative RA (SNRA) by D’Onofrio, et al in npj Autoimmunity shows the diverse fate of seronegative RA - which can resolve, persist or become refractory. Clearly dedicated trials of SNRA are needed to better predict. https://t.co/98VDKucMgX

Pregnancy in Lupus Nephritis and RA: Managing risks and treating to target A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern https://t.co/cTVvyXBbug

📢 "3 months after starting that TNFi ... she was still symptomatic" – Lindsay Tom, PA-C Hear Lindsay discuss this PsA case and her data-informed treatment choices with Dr. Saakshi Khattri. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/6fDS5WoSX5 https://t.co/koqdktQEje

APLAR 2026: The Rheumatologist and AI https://t.co/g81loiW0pI https://t.co/udiw3eoNJr

FDA Approves Tildrakizumab for Psoriatic Arthritis Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis. https://t.co/9vJoJ35iso https://t.co/4ePITTmPl8

Intra-Articular Injections for Knee OA: Options, Evidence, and no Clear Winner At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im. The products fall into three tiers: symptom-modifying, biologic/regenerative https://t.co/jWuinfM2W6

DERM on RheumNow (October 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – Features Dr. Jack Cush, Editor at RheumNow. https://t.co/AfVKHsj47T https://t.co/LlWIKdyFJ1

Exagen studies 192 established RA pts (383 controls) for Abs: CCP2, RF IgA, RF IgM, PAD4 (IgA, IgG). RA signif assoc w/ CCP2+ (OR 110), RF (>7), PAD4 (3.5-5.9). In CCP neg - only PAD4 IgG (2.87) & RF (2.2) assoc w/ RA, w/ only small Dx gain (ΔAUC 0.02–0.04). https://t.co/isf7aMf24O

Spanish Nationwide registry study of 5120 hospitalised #GCA pts (2016-2024) found that 54 (1.1%) Dx / aortic aneurysm (AA) & 41 (0.8%) developed AA on F/U (AAf group). Median time to AA Dx 2.7 yrs. AA Risk was higher in males (RRR 2.42) & smoking w/ GCA (RRR 3.23) https://t.co/eZVGKbOfQt

THe the International Federation of Psoriasis Associations has announced that the 8th World Psoriasis & Psoriatic Arthritis Conference will be taking place in Stockholm on 20–22 May 2027. Registration is open. https://t.co/lq5XdcZlki https://t.co/AYGCnwzeue https://t.co/fy6UUCbcxf

AxSpA SIG Baraliakos - CD74 abs in SpA - what other abs need exploration? @RheumNow #APLAR2026 https://t.co/rftgYQH4mX

Key messages from Dr. Vaidya’s talk: - Assocn’s of hyperuricemia or gout with MetS shows a bidirectional trend - Causality: MetS as an upstream driver for gout devt Going beyond jt dse & ULT. What addt’l assessments do you do for your gout pts? @RheumNow #APLAR2026 https://t.co/M6XVoRQ5rz

Perspective from dentists on SjD dry mouth: muscarinic agonists (pilocarpine, cevimeline) help, but side effects limit use. Two ways to improve it: split pilocarpine dosing (2.5 mg four times daily) and a cevimeline mouth rinse in 6 or more divided doses. #APLAR26 @RheumNow https://t.co/phiLD0qaoR

@RheumNow Do the two fixes work? Split pilocarpine (n=20 SjD, 4 weeks): sweating severity 3.7 to 1.7 (p<0.001), oral dryness VAS 61.0 to 43.6 (p=0.011). Cevimeline rinse (n=12 SjD): unstimulated salivary flow higher than juice control at 1 and 2 h. Small studies. #APLAR26 @RheumNow https://t.co/LEDHFGwh8Q

Lupus/LN should not be a sole indication for a C-section C-section should be reserved for obstetric indications. Adapt a multidisciplinary approach. @RheumNow #APLAR2026 https://t.co/vrXeNP9xLI